115 related articles for article (PubMed ID: 26712061)
21. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia.
Iinuma S; Nagasawa Y; Sasaki K; Hayashi K; Kanno K; Honma M; Sugawara M; Kinouchi M; Obata M; Ishida-Yamamoto A
J Dermatol; 2020 Feb; 47(2):e57-e58. PubMed ID: 31782189
[No Abstract] [Full Text] [Related]
23. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
Paul S; Jain N; Ferrajoli A; O'Brien S; Burger J; Keating M; Wierda W
Br J Haematol; 2019 May; 185(3):606-608. PubMed ID: 30406944
[No Abstract] [Full Text] [Related]
24. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment.
Moulis G; Bagheri H; Sailler L; Jonville-Bera AP; Weber E; Guy C; Petitpain N; Laroche ML; Favrelière S; Béné J; Baldin B; Villeval-Federici L; Tebacher-Alt M; Bres V; Veyrac G; Grandvuillemin A; Mauprivez C; Lapeyre-Mestre M; Montastruc JL;
Eur J Intern Med; 2014 Oct; 25(8):777-80. PubMed ID: 25242516
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Liesveld JL; Phillips GL; Becker M; Constine LS; Friedberg J; Andolina JR; Milner LA; DeBolt J; Smudzin T; Hyrien O; Erickson-Miller CL; Johnson BM; Dawson KL; Chen Y
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1745-52. PubMed ID: 24120380
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
27. No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study.
Lafaurie M; Baricault B; Soler V; Cassagne M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
Br J Haematol; 2020 May; 189(4):e137-e140. PubMed ID: 32155284
[No Abstract] [Full Text] [Related]
28. Eltrombopag-associated hyperpigmentation.
Braunstein I; Wanat KA; Elenitsas R; Xu X; Frey N; Rosenbach M
JAMA Dermatol; 2013 Sep; 149(9):1112-5. PubMed ID: 23884150
[No Abstract] [Full Text] [Related]
29. Severe cutaneous toxicity related to Eltrombopag.
Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A
Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239
[No Abstract] [Full Text] [Related]
30. Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.
Marano M; Serafinelli J; Cairoli S; Martinelli D; Pisani M; Palumbo G; Cefalo MG; Cecchetti C; Di Nardo M; Falvella FS; Goffredo BM
Ther Drug Monit; 2018 Aug; 40(4):386-388. PubMed ID: 29683873
[TBL] [Abstract][Full Text] [Related]
31. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
32. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
[TBL] [Abstract][Full Text] [Related]
33. Molecule of the month. Eltrombopag.
Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
[No Abstract] [Full Text] [Related]
34. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
[No Abstract] [Full Text] [Related]
36. A rare side effect: eltrombopag associated hyperpigmentation.
Atay H; Kelkitli E; Turgut M
G Ital Dermatol Venereol; 2020 Dec; 155(6):803-804. PubMed ID: 31104458
[No Abstract] [Full Text] [Related]
37. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
38. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Bruno S; Sewpaul P; Russo ML; Boccaccio V; Almasio PL; Giannini EG
Dig Liver Dis; 2015 Oct; 47(10):864-8. PubMed ID: 26187555
[TBL] [Abstract][Full Text] [Related]
39. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
40. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
